Discover the X Factor in Wound Care
BlastX™ is a breakthrough antimicrobial wound gel powered by Next Science’s patented, non-toxic, biofilm-disruption Xbio™ technology. It deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment.29
Others only address the tip of the iceberg.
BlastX™ goes deeper to help solve the
problem of bacterial biofilm:
Mayo Clinic Study Reveals BlastX™ Significantly Improves Wound Area Reduction and Closure*
A 12-week, randomized, open-label clinical trial at Mayo Clinic Jacksonville, FL, demonstrated the healing power of BlastX.
‣‣Wound Area Reduction:
69% (more than 2.4x) greater area reduction for BlastX vs. 29% for control (P < 0.001)
Average wound size – 11cm2; Average wound duration – 21 months; Average pt. Age – 61
‣‣Wound Closure: 213%* relative increase in healing versus control (52% BlastX vs. 17% control)
Clinical and Scientific Studies on Biofilm Disruption and BlastX™
For additional clinical and scientific studies about biofilms and BlastX’s performance, download the following publications:
Randomized Control Trail Determines BlastX Biofilm-Disruption Therapeutically Efficacious in Chronic Wounds
Kim D, Namen W, Moore J, Buchanan M, Hayes V, Myntti M, Hakaim A. Clinical Assessment of a Biofilm-disrupting Agent for the Management of Chronic Wounds Compared With Standard of Care: A Therapeutic Approach. Wounds. Epub 2018.
Pivotal Randomized Control Trial Demonstrates BlastX improved Wound Healing
In A Category of its Own: BlastX Proves Effective Against Bacterial Biofilms
Miller KG, Tran PL, Haley CL, et al. Next science wound gel technology, a novel agent that inhibits biofilm development by gram-positive and gram-negative wound pathogens. Antimicrob Agents Chemother. 2014;58(6):3060–3072.
U.S. Consensus Paper focuses on the Importance of Biofilm Disruption in Treating Chronic Wounds and calls out the promise of high osmolarity surfactant technology
Snyder RJ, Bohn G, Hanft J, Harkless L, Kim P, Lavery L, Schultz G, Wolcott R. Wound Biofilm: Current Perspectives and Strategies on Biofilm Disruption and Treatments. Wounds: a compendium of clinical research and practice. 2017 Jun;29(6):S1-S17.
Additional Published Biofilm Education
The Emerging Science of Biofilm: Shifting the Spotlight to the Biofilm Structure: Why Only Targeting the Bacteria in Wounds is Not Enough
Debridement: The Next Clinical Advantage in TIME
Outliers: Reexamining Wounds that Fail to Heal
Attacking Biofilm Structure: Latest Wound Healing Data Shifts Spotlight
Integrating Emerging Research into Biofilm Management: Targeting the Biofilm Structure
Elevate Your Standard of Care with Effective Antibiofilm Technology
This peer-reviewed paper supports the need for a paradigm shift toward biofilm disruption strategies for wound healing.
‣‣Upgrade your standard of care: Follow this recommended step-down/step-up approach with the use of biofilm-disruption technology for the treatment of wounds.
Independent testing conducted at the Montana State University Center for Biofilm Engineering
BlastX™ Supersedes Current Therapy by Reducing Biofilm Bacteria 4-6 Log in Laboratory Tests24,41
In in vitro studies, BlastX was compared to multiple current topical antimicrobial therapies. 24 hours after application, measurements were taken for two different kinds of biofilm bacteria (S. aureus and P. aeruginosa).
BlastX is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial- and full-thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second degree burns, and grafted and donor sites.
BlastX is non-toxic and compatible with a broad range of advanced healing modalities that set the stage for better preparation and ongoing care of the wound bed.
MPN-WEB-003 Rev B